A closed-end investment fund that provides public market exposure to biotechnology, pharmaceutical, and broader life sciences companies. The portfolio is actively managed and typically holds a mix of large-cap drugmakers and smaller biotech firms, with a mandate to generate long-term capital appreci...
2 members of Congress have disclosed 8 trades in Tekla Life Sciences Investors (HQL), a Financial Services company. The buy/sell breakdown shows 5 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-10-04 | Thomas R Carper | sell | $1K – $15K |
| 2020-02-22 | Thomas R Carper | buy | $1K – $15K |
| 2016-09-19 | RAUL M. GRIJALVA | sell | $1K – $15K |
| 2016-02-12 | RAUL M. GRIJALVA | buy | $1K – $15K |
| 2016-01-13 | RAUL M. GRIJALVA | buy | $1K – $15K |
| 2015-10-15 | RAUL M. GRIJALVA | buy | $1K – $15K |
| 2015-07-14 | RAUL M. GRIJALVA | sell | $1K – $15K |
| 2014-02-21 | RAUL M. GRIJALVA | buy | $1K – $15K |